BeOne Medicines
ONCONC · Stock Price
Historical price data
Overview
BeOne Medicines is a global, publicly traded oncology company with a mission to deliver transformative cancer treatments through scientific excellence and rapid execution. The company has established itself with two commercial-stage assets, BRUKINSA and TEVIMBRA, and a deep, multi-modality pipeline targeting high-burden blood cancers, solid tumors, and rare malignancies. Its strategy leverages a global clinical and commercial footprint, significant R&D investment, and a multi-platform technology approach to capture substantial market opportunities in oncology.
Technology Platform
A multi-modality platform encompassing targeted therapies (BTK, BCL2 inhibition) and novel modalities like the Chimeric Degradation Activation Compound (CDAC) platform for targeted protein degradation.
Pipeline
84| Drug | Indication | Stage | Watch |
|---|---|---|---|
| Zanubrutinib | Waldenström's Macroglobulinemia | Approved | |
| Tislelizumab + Pamiparib + Temozolomide + Sitravatinib + Oci... | Advanced Malignancies | Phase 3 | |
| Zanidatamab + Tislelizumab + Trastuzumab + Capecitabine + Ox... | Gastric Neoplasms | Phase 3 | |
| Zanubrutinib + Bendamustine + Rituximab + Venetoclax | Chronic Lymphocytic Leukemia | Phase 3 | |
| Tislelizumab + Placebo + Cisplatin + Gemcitabine Hydrochlori... | Urothelial Carcinoma | Phase 3 |
Funding History
3FDA Approved Drugs
3Opportunities
Risk Factors
Competitive Landscape
BeOne faces fierce competition in its core areas: against AbbVie, AstraZeneca, and others in BTK inhibition; against Merck and Bristol Myers Squibb in PD-1 inhibition; and against a host of biotechs and large pharma in novel modalities like protein degradation. Its integrated global model is a key differentiator.